Trade

with

Pfizer Inc
(NYSE: PFE)
AdChoices
28.84
+0.53
+1.87%
After Hours :
-
-
-

Open

28.65

Previous Close

28.31

Volume (Avg)

5.19M (24.71M)

Day's Range

28.60-28.84

52Wk Range

27.51-32.96

Market Cap.

179.45B

Dividend Rate (Yield )

1.04 (3.60%)

Beta

0.67

Shares Outstanding

6.34B

P/E Ratio (EPS)

17.83 (1.59)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Drug Manufacturers – Major
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 51.58B

    • Net Income

    • 22.00B

    • Market Cap.

    • 179.45B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 20.66

    • PEG (Price/Earnings Growth) Ratio

    • 6.50

    • Beta

    • 0.67

    • Forward P/E

    • 12.77

    • Price/Sales

    • 3.67

    • Price/Book Value

    • 2.34

    • Price/Cash flow

    • 9.75

      • EBITDA

      • 23.54B

      • Return on Capital %

      • 5.91

      • Return on Equity %

      • 13.41

      • Return on Assets %

      • 5.91

      • Book Value/Share

      • 12.08

      • Shares Outstanding

      • 6.34B

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • 0.26 (7/30/2014)

      • Dividend Declaration Date

      • 6/26/2014

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 34.33

        • Credit Rating

        • AA

        • Analysts

        • 5

        • EPS Estimate

        • 1.96

        • Cashflow Estimate

        • 2.74

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -1.50

          • 0.89

          • Net Income

            YTD/YTD (last year)

          • 19.50

          • 7.80

          • Net Income

            Q/Q (last year)

          • -17.60

          • 4.50

          • Sales (Revenue)

            5-Year Annual Average

          • 1.33

          • 6.10

          • Net Income

            5-Year Annual Average

          • 7.20

          • 3.73

          • Dividends

            5-Year Annual Average

          • -5.59

          • 2.17

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 80.95

            • 69.92

            • Pre-Tax Margin

            • 26.79

            • 21.84

            • Net Profit Margin

            • 20.66

            • 18.37

            • Average Gross Margin

              5-Year Annual Average

            • 79.60

            • 71.90

            • Average Pre-Tax Margin

              5-Year Annual Average

            • 21.10

            • 21.92

            • Average Net Profit Margin

              5-Year Annual Average

            • 22.30

            • 903.40B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.42

              • 0.32

              • Current Ratio

              • 2.66

              • 1.92

              • Quick Ratio

              • 2.03

              • 1.31

              • Interest Coverage

              • -

              • 17.64

              • Leverage Ratio

              • 2.25

              • 2.03

              • Book Value/Share

              • 12.08

              • 14.72

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 17.61

                • 22.12

                • P/E Ratio 5-Year High

                • 20.76

                • 193.96

                • P/E Ratio 5-Year Low

                • 8.82

                • 87.26

                • Price/Sales Ratio

                • 3.63

                • 3.75

                • Price/Book Value

                • 2.31

                • 3.75

                • Price/Cash Flow Ratio

                • 9.75

                • 14.03

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • 13.41

                    (15.70)

                  • 17.42

                    (18.66)

                  • Return on Assets %

                    (5-Year Average)

                  • 5.91

                    (6.90)

                  • 8.45

                    (8.77)

                  • Return on Capital %

                    (5-Year Average)

                  • 9.96

                    (11.60)

                  • 12.41

                    (13.18)

                  • Income/Employee

                  • 133.84k

                  • 90.07k

                  • Inventory Turnover

                  • 1.53

                  • 2.46

                  • Asset Turnover

                  • 0.29

                  • 0.46

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  15.72B
                  Operating Margin
                  30.47
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  9.75
                  Ownership

                  Institutional Ownership

                  73.90%

                  Top 10 Institutions

                  21.88%

                  Mutual Fund Ownership

                  36.14%

                  Float

                  99.98%

                  5% / Insider Ownership

                  0.23%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Total Stock Mkt Idx

                  •  

                    103,915,619

                  • 0.43

                  • 1.64

                  • Vanguard Five Hundred Index Fund

                  •  

                    65,828,953

                  • -0.36

                  • 1.04

                  • Vanguard Institutional Index Fund

                  •  

                    64,240,391

                  • -1.64

                  • 1.01

                  • SPDR® S&P 500 ETF

                  •  

                    61,439,784

                  • -0.67

                  • 0.93

                  • VA CollegeAmerica Income Fund of America

                  •  

                    56,230,000

                  • 1.35

                  • 0.89

                  • Franklin Income Fund

                  •  

                    45,000,000

                  • 12.50

                  • 0.71

                  • Vanguard Windsor™ II Fund

                  •  

                    44,416,681

                  • 5.66

                  • 0.70

                  • MFS® Value Fund

                  •  

                    32,765,471

                  • 0.00

                  • 0.52

                  • Vanguard Wellington™

                  •  

                    29,075,738

                  • 0.00

                  • 0.46

                  • Dodge & Cox Stock Fund

                  •  

                    29,071,064

                  • -3.36

                  • 0.46

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Group, Inc.

                  •  

                    327,984,566

                  • +1.72%

                  • 5.14

                  • State Street Corp

                  •  

                    267,871,506

                  • +0.79%

                  • 4.20

                  • BlackRock Fund Advisors

                  •  

                    203,559,323

                  • +3.99%

                  • 3.19

                  • Capital World Investors

                  •  

                    123,802,400

                  • +1.64%

                  • 1.94

                  • Wellington Management Company, LLP

                  •  

                    96,042,937

                  • +10.11%

                  • 1.51

                  • Northern Trust Investments, N.A.

                  •  

                    95,265,904

                  • -1.00%

                  • 1.49

                  • MFS Investment Management K.K.

                  •  

                    84,061,357

                  • -2.09%

                  • 1.32

                  • T. Rowe Price Associates, Inc.

                  •  

                    83,709,399

                  • -20.32%

                  • 1.31

                  • Pfizer Savings Plan

                  •  

                    67,339,776

                  • +15.91%

                  • 0.83

                  • State Farm Mutual Automobile Ins CO

                  •  

                    60,607,997

                  • 0.00%

                  • 0.95

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Drug Manufacturers – Major

                  Type

                  Slow Growth

                  Style

                  Large Value

                  Pfizer Inc was incorporated under the laws of the State of Delaware on June 2, 1942. It is a research-based, biopharmaceutical company. The Company applies science and its global resources to bring therapies to people that extend and...more improve their lives through the discovery, development and manufacture of healthcare products. The Company’s portfolio includes medicines and vaccines, as well as many of the world’s known consumer healthcare products. They managed its operations through four operating segments-Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; and Consumer Healthcare. Primary Care operating segment-included revenues from prescription pharmaceutical products primarily prescribed by primary-care physicians, and included products in the following therape...moreutic and disease areas: Alzheimer’s disease, cardiovascular (excluding pulmonary arterial hypertension), erectile dysfunction, and genitourinary, major depressive disorder, and pain, respiratory and smoking cessation. Specialty Care and Oncology operating segment-was comprised of the Specialty Care business unit and the Oncology business unit. Established Products segment included revenues from prescription pharmaceutical products that had lost patent protection or marketing exclusivity in certain countries and/or regions. Emerging Markets-included revenues from all prescription pharmaceutical products sold in emerging markets, including Asia excluding Japan and South Korea, Latin America, the Middle East, Eastern Europe, Africa, Turkey and Central Europe. Consumer Healthcare operating segment-includes worldwide revenues from non-prescription products in the following therapeutic categories: dietary supplements, pain management, respiratory and personal care. In 2013, products marketed by Consumer Healthcare included Advil, Caltrate, Centrum, ChapStick, Emergen-C, Preparation H and Robitussin. In its global biopharmaceutical businesses, they promote its products to healthcare providers and patients. The Company also markets directly to consumers in the U.S. through direct-to-consumer advertising that communicates the approved uses, benefits and risks of its products while motivating people to have meaningful conversations with their doctors. Its biotechnology products, including BeneFIX, ReFacto, Xyntha, Enbrel and the Prevnar family, may face competition in the future from biosimilars. The Company competes with other companies that manufacture and sell products that treat diseases or indications similar to those treated by its major products. The Company is subject to extensive regulation by national, state and local agencies in the countries in which they do business.lessless

                  Key People

                  Ian C. Read

                  CEO/Chairman of the Board/Director

                  Frank A. D'Amelio

                  CFO/Executive VP, Divisional

                  Sally Susman

                  Executive VP, Divisional

                  Dr. Freda C. Lewis-Hall,M.D.

                  Chief Medical Officer/Executive VP

                  Douglas M. Lankler

                  Executive VP/General Counsel

                  • Pfizer Inc

                  • 235 East 42nd Street

                  • New York, NY 10017-5755

                  • USA.Map

                  • Phone: +1 212 733-2323

                  • Fax: -

                  • pfizer.com

                  Incorporated

                  1942

                  Employees

                  77,700

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: